Physician profile
Jane E Pahud
NPI 1487339990
$12,214.76
in general payments reported to CMS, 2019-2025
27 companies · $2,960 in 2025
The $2,960 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $301 · 2024: $8,954 · 2025: $2,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,907 · Travel and Lodging: $3,349 · Consulting Fee: $1,925 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,907.37 |
| Travel and Lodging | $3,348.95 |
| Consulting Fee | $1,925.00 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $3,616.27 | 2023-2025 | Vyvgart Hytrulo |
| Abbott Laboratories | $1,735.77 | 2025 | Infinity, Proclaim |
| Livanova USA, INC. | $1,683.96 | 2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $912.88 | 2023-2025 | |
| Ucb, INC. | $886.59 | 2024-2025 | Fintepla, Briviact, Nayzilam |
| Lundbeck LLC | $474.02 | 2023-2025 | Vyepti |
| Pfizer INC. | $440.99 | 2023-2025 | |
| Sk Life Science, INC. | $396.03 | 2023-2024 | Xcopri |
| Inspire Medical Systems, INC. | $265.57 | 2024 | Inspire |
| Catalyst Pharmaceuticals, INC. | $248.71 | 2023-2025 | Firdapse |
| Alexion Pharmaceuticals, INC. | $232.17 | 2023-2025 | Ultomiris |
| Emd Serono, INC. | $211.81 | 2024 | Mavenclad |
| Medtronic, INC. | $199.72 | 2024 | Percept PC Brainsense |
| Teva Pharmaceuticals USA, INC. | $158.49 | 2024-2025 | Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $137.11 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.06 | 2024 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $93.44 | 2024 | Hyqvia |
| Biogen, INC. | $83.93 | 2024-2025 | Skyclarys, Vumerity, Tysabri |
| Merz Pharmaceuticals, LLC | $60.98 | 2025 | Inbrija, Xeomin |
| Acorda Therapeutics, INC | $52.40 | 2023-2024 | Inbrija |
| Csl Behring | $48.42 | 2024 | Hizentra |
| Nevro Corp. | $33.87 | 2024 | Senza |
| Celgene Corporation | $26.79 | 2023 | Zeposia |
| Tg Therapeutics, INC. | $25.40 | 2024 | |
| Acadia Pharmaceuticals INC | $23.57 | 2024 | Nuplazid |
| Tonix Medicines, INC. | $22.13 | 2025 | Zembrace Symtouch |
| Cala Health, INC. | $20.68 | 2024 | Cala Trio, Cala Kiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Pahud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.